Editas Medicine Inc (EDIT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Editas Medicine Inc (EDIT) has a cash flow conversion efficiency ratio of -2.293x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.84 Million) by net assets ($13.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Editas Medicine Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Editas Medicine Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read EDIT total debt and obligations for a breakdown of total debt and financial obligations.
Editas Medicine Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Editas Medicine Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CMG Pharmaceutical Co. Ltd
KQ:058820
|
-0.020x |
|
DCW Limited
NSE:DCW
|
0.123x |
|
Contextlogic Inc
NASDAQ:LOGC
|
-0.023x |
|
Streamwide
PA:ALSTW
|
0.363x |
|
Bastide Le Confort Médical SA
PA:BLC
|
0.479x |
|
Yuan Jen Enterprises Co Ltd
TW:1725
|
0.071x |
|
Dream Security co. Ltd
KQ:203650
|
-0.051x |
|
Sanstar Ltd
NSE:SANSTAR
|
0.067x |
Annual Cash Flow Conversion Efficiency for Editas Medicine Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Editas Medicine Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see Editas Medicine Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $134.27 Million | $-210.28 Million | -1.566x | -313.62% |
| 2023-12-31 | $349.10 Million | $-132.18 Million | -0.379x | +23.00% |
| 2022-12-31 | $360.68 Million | $-177.35 Million | -0.492x | -66.19% |
| 2021-12-31 | $553.64 Million | $-163.80 Million | -0.296x | +35.25% |
| 2020-12-31 | $393.59 Million | $-179.84 Million | -0.457x | -194.86% |
| 2019-12-31 | $262.44 Million | $-40.67 Million | -0.155x | +19.93% |
| 2018-12-31 | $236.16 Million | $-45.71 Million | -0.194x | -327.65% |
| 2017-12-31 | $208.08 Million | $-9.42 Million | -0.045x | +87.80% |
| 2016-12-31 | $134.61 Million | $-49.93 Million | -0.371x | -670.56% |
| 2015-12-31 | $-83.11 Million | $-5.40 Million | 0.065x | -88.51% |
| 2014-12-31 | $-15.29 Million | $-8.65 Million | 0.566x | -64.16% |
| 2013-12-31 | $-1.76 Million | $-2.78 Million | 1.579x | -- |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors… Read more